5.1.3.13	1-(3-(5-allyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylsulfonyl)-propyl)-1H-benzo[d]imidazol-2(3H)-one	-	78294	
5.1.3.13	1-(3-(5-allyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	i.e. 77074, a SID 7975595 analogue	78291	
5.1.3.13	1-(3-(5-allyl-8-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	-	78292	
5.1.3.13	1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylsulfonyl)-propyl)-1H-benzo[d]imidazol-2(3H)-one	-	78293	
5.1.3.13	1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	i.e. SID 7975595, a competitive, fast-on rate, fully reversible inhibitor of RmlC. Increases the Km for TDP-6-deoxy-D-xylo-hexopyranosid-4-ulose. Cytotoxic SID 7975595 has an IC50 of approximately 0.075 mM in HAE cells	78286	
5.1.3.13	1-(3-(5-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	i.e. 77072, a SID 7975595 analogue	78289	
5.1.3.13	1-(3-(5-methylphenyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	i.e. 77070, a SID 7975595 analogue	78287	
5.1.3.13	1-(3-(5-propyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	i.e. 77071, a SID 7975595 analogue	78288	
5.1.3.13	1-(3-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one	i.e. 77073, a SID 7975595 analogue	78290	
5.1.3.13	additional information	modeling of triazinoindol-benzimidazolones into the active site of RmlC, overview	2